Overview

A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of additional quilizumab therapy in adult patients with Chronic Spontaneous Urticaria resistant to antihistamine treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.